Palladium(II) compounds with potential antitumour properties and their platinum analogues: A comparative study of the reaction of some erotic acid derivatives with DNA in vitro

Chemico-Biological Interactions

Volumn 104, Issue 2-3, 1997, Pages 165-178

  Butour, J L ^a   Wimmer, S ^b   Wimmer, F ^b   Castan, P ^c  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITI BRUNEI DARUSSALAM   (Brunei Darussalam)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Antitumour activity; DNA metal complexes; Orotic acid metal compounds; Palladium compounds; Platinum compounds

Indexed keywords

ANTINEOPLASTIC AGENT; METAL COMPLEX; OROTIC ACID DERIVATIVE; PALLADIUM COMPLEX; PLATINUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA BINDING; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL DIVISION; CELL TRANSPLANTATION; DNA, NEOPLASM; HYDROLYSIS; KINETICS; LIGANDS; MALE; MICE; NEOPLASM TRANSPLANTATION; OROTIC ACID; PALLADIUM; PLATINUM COMPOUNDS; SALMON; SARCOMA 180; SPECTROPHOTOMETRY, ULTRAVIOLET; SPERMATOZOA; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0030991487     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00022-7     Document Type: Article

References (37)

1. A.W. Prestayko, S.T. Crooke and S.K. Carter, Cisplatin: current status and new developments, Academic Press, New-York, 1980.
2. D.S. Gill, Structure activity relationship of antitumor palladium complexes, in: M.P. Hacker, E.B. Douple and I.K. Krakoff, (Eds.), Platinum coordination complexes in cancer chemotherapy, Martinus Nijhoff Publishing, 1984, pp. 267-278.
3. R.B. Weiss and M.V.C. Christian, New cisplatin analogues in development, Drugs, 46 (1993) 360-367.
4. L.R. Kelland, New platinum antitumor complexes, Crit. Rev. Oncol. Hematol., 15 (1993) 191-219.
5. M.J. Cleare, P.C. Hydes, B.W. Malerbi and D.M. Watkins, Antitumor platinum complexes: relationship between chemical properties and activity. Biochimie, 60 (1978) 835-850.
6. I.E. Smith and B.D. Evans, Carboplatin (JM8) as a single agent and in combination in the treatment of a small cell lung cancer, Cancer Treat. Rev., 12 (1985) 73-75.
7. J.A. Howle and G.R. Gale, Cis-dichlorodiammineplatinum(II), persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol., (1970) 19.
8. H.C. Harder and B. Rosenberg, Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein synthesis in mammalian cells in vitro. Int. J. Cancer, 6 (1970) 207-216.
9. L.A. Pinto and S.J. Lippard, Binding of the antitumor drug cis-diamminedichloroplatinum(II) (Cisplatin) to DNA, Biochim. Biophys. Acta, 780 (1985) 167-180.
10. P. Umpathy, The chemical and biochemical consequences of the binding of the antitumour drug cisplatin and other platinum metal complexes to DNA. Coord. Chem. Rev., 95 (1989) 129-181.
11. N.P. Jonhson, J.L. Butour, G. Villani, F.L. Wimmer, M. Defais, V. Pierson and V. Brabec, Metal antitumor compounds: the mechanism of action of platinum complexes. Prog. Clin. Biochem. Med., 10 (1989) 1-24.
12. M.J. Clarke, in: M. Dekker (Ed.), Metal Ions in Biological Systems, New-York, Vol 11, 1979, pp. 231-283.
13. M.J. Clarke, Ruthenium anticancer agents and relevant reactions of ruthenium-purine complexes, in: S.J. Lippard (Ed.), Platinum, gold and other chemotherapeutic agents. ACS Symposium series 209, 1983, pp. 334-354.
14. M.J. Clarke, R.D. Galang, V.M. Rodriguez, R. Kumar, S. Pell and D.M. Bryan, Chemical consideration in the design of ruthenium anticancer agents, in: M. Nicolini (Ed.), Platinum and other coordination compounds in cancer chemotherapy, M. Nijihoff Publishing, 1987, pp. 582-600.
15. C.K. Mirabelli, R.K. Johnson, D.T. Hill, L.F. Faucette, G.R. Girard, G.Y. Kuo, C.M. Sung and S.T. Crooke, Correlation in the in vitro cytotoxic and in vivo antitumor activity of gold(I) coordination complexes. J. Med. Chem., 29 (1986) 218-233.
16. B.K. Keppler, H. Bischoff, M.R. Berger, M.E. Heim and D. Schamahl, Preclinical development and clinical studies of budotitane, in: M. Nicolini and G. Bandoli (Ed.), Platinum and other metal coordination compounds in cancer chemotherapy, Cleup Padua, (1987) 313-315.
17. P. Castan, E. Colacio-Rodriguez, A.L. Beauchamp, S. Cros and S. Wimmer, Platinum and palladium complexes of 3-methyl orotic acid: a route toward palladium complexes with good antitumor activity. J. Inorg. Biochem., 38 (1990) 225-239.
18. P. Arrizabalaga, P. Castan and J.P. Laurent, Carboxy uracil and some of its derivatives as complexant toward platinum. Platinum blues. Inorg. Chim. Acta, 92 (1984) 203-208.
19. P. Arrizabalaga, P. Castan and J.P. Laurent, Palladium(II) complexes of orotic acid and derivatives: multiplicity of their binding sites. J. Inorg. Biochem., 20 (1984) 215-224.
20. J.B. Le Pecq, Use of ethidium bromide for separation and determination of nucleic acids of various conformational forms and measurement of their associated enzymes. Methods Biochem. Anal. 20 (1971) 41-86.
21. G. Scatchard, The attraction of proteins for small molecules and ions. Ann. N.Y. Acad Sci., 51 (1949) 660-674.
22. J.B. Le Pecq and C. Paoletti, A fluorescent complex between ethidium bromide and nucleic acids. J. Mol. Biol. 27 (1967) 87-106.
23. J.L. Butour, A.M. Mazard and J.P. Macquet, Kinetics of the reaction of cis-platinum compounds with DNA in vitro, Biochem. Biophys. Res. Comm., 133 (1985) 347-353.
24. J.P. Macquet and J.L. Butour, Modifications of the DNA secondary structure upon platinum binding: a proposed model. Biochimie, 60 (1978) 901-914.
25. F.L. Wimmer, S. Wimmer, P. Castan, S. Cros, N. Johnson and E. Colacio-Rodriguez, The antitumor activity of some palladium(II) complexes with chelating ligands, Anticancer Res., 9 (1989) 791-794.
26. J.P. Macquet and J.L. Butour, Platinum-amine compounds: Importance of the labile and inert ligands for their pharmacological activities toward L1210 leukemia cells, J. Natl. Cancer Int., 70 (1983) 899-905.
27. J.L. Butour and J.P. Macquet, Differentiation of DNA-platinum complexes by fluorescence: the use of an intercalating dye as a probe, Eur. J. Biochem., 78 (1977) 455-463.
28. J.L. Butour and J.P. Macquet, Viscosity, nicking, thermal and alkaline denaturation studies on three classes of DNA-platinum complexes, Biochim. Biophys. Acta, 653 (1981) 305-315.
29. C. Navarro-Ranninger, J.M. Perez, F. Zamora, V.M. Gonzalez, J.R. Masaguer and C. Alonso, Palladium(II) compounds of putrescine and spermine. Synthesis, characterization, and DNA-binding and antitumor properties, J. Inorg. Biochem., 52 (1993) 37-49.
30. H. Mansuri-Torshizi, T.S. Srivastava, S.J. Chavan and M.P. Chitnis, Cytotoxicity and DNA binding studies of several platinum(II) and palladium(II) complexes of the 2,2′-bipyridine and an anion of 2-pyridinecarboxylic/2-pyrazinecarboxylic acid, J. Inorg. Biochem., 48 (1992) 63-70.
31. R. Mital, T.S. Srivastava, H.K. Parekh and M.P. Chitnis, Synthesis, characterization, DNA binding, and cytotoxic studies of some mixed ligand palladium(II) and platinum(II) complexes of a diimine and amino acids, J. Inorg. Biochem., 41 (1991) 93-103.
32. C.F.J. Barnard, M.J. Cleare and P.C. Hydes, Second generation anticancer platinum compounds, Chem. Br., 22 (1986) 1001-1004.
33. L.A. Zwelling, Cancer chemiotherapy and biological response modifiers, H.M. Pinedo, D.L. Longo and B.A. Chabners (Eds.), Elsevier Amsterdam, 9 (1987) 71-75.
34. J.F. Vollano, S. Al-Baker, J.C. Dabrowiak and J.E. Schurig, Comparative study of platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane, J. Med. Chem., 30 (1987) 716-719.
35. D.S. Gill and B. Rosenberg, Syntheses, kinetics, and mechanism of formation of polynuclear hydroxo-bridged complexes of (trans-1,2-diaminocyclohexane)platinum(II), J. Am. Chem. Soc., 104 (1982) 4598-4604.
36. H.M. Pinedo and G.F.J. Peters, Fluorouracil: biochemistry and pharmacology, J. Clin. Oncol., 6 (1988) 1653-1664.
37. J.L. Butour and J.P. Macquet, Platinum determination in DNA-platinum complexes by fluorescence spectrophotometry, Analyt. Biochem., 89 (1978) 22-30.